Food Allergens

Developing Assays Across Food Allergens

AllerGenis’ researchers are developing a pipeline of assays across a broad array of food allergens. Founded on the epitope mapping research of Hugh Sampson, MD, of the Jaffe Food Allergy Institute of the Icahn School of Medicine at Mount Sinai, our diagnostic technology subdivides allergenic proteins into smaller peptides, called epitopes, and measures the reactivity of a patient’s IgE to these epitopes. The platform uses a high-throughput, bead-based epitope assay (BBEA) to analyze IgE reactivity to discrete food allergen epitopes from only a few microliters of patient plasma in a CLIA certified, clinical lab setting.

VeriMAP™ Peanut
Research/ Biomarker Discovery*
Assay Development
Analytical Validation
Clinical Validation
Commercial Launch

Peanut Diagnostic

Peanut Diagnostic
Research/ Biomarker Discovery* Assay Development Analytical Validation Clinical Validation Commercial Launch

Reactivity Threshold

Reactivity Threshold
Research/ Biomarker Discovery* Assay Development Analytical Validation

Rx Response

Rx Response
Research/ Biomarker Discovery* Assay Development Analytical Validation
VeriMAP™ Milk

Milk Diagnostic

Milk Diagnostic
Research/ Biomarker Discovery* Assay Development

Reactivity Threshold

Reactivity Threshold
Research/ Biomarker Discovery* Assay Development

Milk Form

Milk Form
Research/ Biomarker Discovery* Assay Development

Milk Outgrowth

Milk Outgrowth
Research/ Biomarker Discovery*

Rx Response

Rx Response
Research/ Biomarker Discovery*
VeriMAP™ Egg

Egg Diagnostic

Egg Diagnostic
Research/ Biomarker Discovery* Assay Development

Reactivity Threshold

Reactivity Threshold
Research/ Biomarker Discovery*

Egg Form

Egg Form
Research/ Biomarker Discovery*

Egg Outgrowth

Egg Outgrowth
Research/ Biomarker Discovery*

Egg Rx Response

Egg Rx Response
Research/ Biomarker Discovery*

*Epitope Panel Identification

value of Allergenis
Platform is clear

The AllerGenis high throughput multiplex Luminex bead based epitope assay (BBEA) enables clear quantification and the screening of samples and epitopes with smaller volumes of plasma. 

The epitope platform is the only diagnostic platform validated against oral food challenge, the gold standard for allergy diagnostics.

Blood-based epitope mapping is performed without the risk of triggering an allergic reaction and may lessen patient anxiety.

robust technology

Robust Technology

In full development, the goal of the AllerGenis 
technology program will be the ability to:

  • Diagnose patient food allergy and associated disease severity (including anaphylaxis) without the risks associated with oral food challenge.
  • Distinguish between a sensitized patient and allergic disease, and who will naturally outgrow.
  • Assess progression of desensitization during immunotherapy.

 

AllerGenis  technology program